MiR-381-3p/RAB2A axis activates cell proliferation and inhibits cell apoptosis in bladder cancer

Sun, Xiaolu; Hu, Xiufang; Wang, Xiangtao; Jiang, Xianzhou

doi:10.14715/cmb/2020.66.6.21

Cited by 9 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A research of bladder cancer in vitro showed miR-381-3p inhibits the progression of bladder cancer cells by binding to RAB2A (Ras-Related Protein Rab-2A). Another experiment also proved that miR-381-3p blocks the dual regulatory role of CCNA2 (Cyclin-A2) in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression in bladder cancer [ 30 , 31 ]. Identical to miR-381-3p, miR-451a acts as anti-cancer factor in various cancer and inhibits the proliferation, migration and invasion of cancer cells [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

A serum miRNAs signature for early diagnosis of bladder cancer

Lai

2023

Annals of Medicine

View full text Add to dashboard Cite

Background Bladder cancer accounts for the most common type of urologic malignancy and presents high recurrence rate after surgical resection and adjuvant intravesical therapy. We aim to search for an early diagnostic biomarker in serum for bladder cancer in this study. Methods The expression profiles of miRNAs in serum samples of 112 bladder cancer patients and 112 healthy controls were detected with real-time polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve and area under curve (AUC) analysis were performed to assess the diagnostic efficiency of miRNAs. Stepwise logic regression analysis was used to construct a diagnostic signature with highest sensitivity and specificity. Bioinformatics analysis was applied to explore the potential biological functions and mechanisms of candidate miRNAs. Results Five miRNAs including miR-451a, miR-381-3p, miR-223-3p, miR-142-5p and miR-27b-3p were found differentially expressed in serum samples of bladder patients and healthy subjects. The diagnostic signature was constructed with miR-27b-3p, miR-381-3p and miR-451a. AUC of the three-miRNA signature was 0.894 (0.837–0.936, p < 0.001). The sensitivity and specificity of this signature were 86.90% and 77.38%, respectively, indicating that this signature has a good ability to diagnose bladder cancer. Conclusion The three-miRNA signature we constructed has favorable diagnostic capacity and may be a promising non-invasive biomarker in the early diagnosis of bladder cancer. KEY MESSAGES There is still no clinical utilization of serum miRNAs in the early detection of bladder cancer. We screened and constructed a three-miRNA signature with the sensitivity of 86.90% and specificity of 77.38% which may be a promising non-invasive biomarker in the early diagnosis of bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A serum miRNAs signature for early diagnosis of bladder cancer

Lai

2023

Annals of Medicine

View full text Add to dashboard Cite

show abstract

“…Thus, Rab proteins regulate signal transduction, cell development, and differentiation. Previous research has shown that abnormal Rab expression is strongly linked to genetic problems, in ammation, neurological disorders 18 , diabetes 19 , and a variety of cancers 20 , such as bladder cancer 21 , breast cancer 5,22,23 , oral cancer 24 , and glioblastoma.…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of RAB2A as a new prognostic biomarker for breast cancer

Lin

Mao

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Targeting GTPase 2A(RAB2A) is overexpressed in a variety of malignancies and plays an essential role in tumor formation. However, the predictive significance of RAB2A in breast cancer remains undetermined. Methods:In this study, breast cancer patients' expression profiles and clinical data were extracted from The Cancer Genome Atlas (TCGA) database. Using the Wilcoxon rank sum test, RAB2A expression levels were compared between breast cancer and normal breast tissue. An enrichment analysis was performed to investigate potential signaling pathways and associated biological activities. Using single-sample gene set enrichment analysis, the invasion of immune cells was evaluated. Utilizing Ualcan and the MethSurv database, the methylation status of RAB2A was determined. Using the Kaplan-Meier technique and Cox regression analysis, the prognostic value of RAB2A was determined. A nomogram was developed to predict overall survival (OS) one, three, and five years following cancer diagnosis. Results: RAB2A was substantially linked with higher PR, ER status, N grade, histological type, PAM50, and age and was overexpressed in breast cancer.Overexpression of RAB2A significantly decreased overall survival and disease-specific survival. RAB2A was found as an independent negative predictive factor for OS by multivariate Cox analysis. The concordance index of the OS nomogram generated was 0.72. Similarly, RAB2A hypomethylation was related with a bad outcome. Analysis of functional enrichment revealed that keratinocyte development, humoral immune response pathway, IL-16 signaling pathway, cytokine-receptor interactions, immune response regulatory signaling pathway, and taste transduction were among the enriched pathways. In addition, RAB2A overexpression was negatively linked with the number of necrotizing cells, CD8+ T cells, dendritic cells, and plasmacytoid dendritic cells that infiltrated the tissue. Conclucion:RAB2A may serve as a possible breast cancer prognostic biomarker and therapeutic target. Our findings establish the groundwork for future research into the molecular mechanisms of RAB2A in breast cancer and are essential for clarifying RAB2A's therapeutic relevance in breast cancer.

show abstract

“…MiR-522-3p is an oncogene in glioblastoma by targeting SFRP2 through the Wnt/β-catenin pathway [ 42 ]. The miR-381-3p/RAB2A axis induces cell proliferation and inhibits cell apoptosis in bladder cancer [ 43 ]. MiR-381-3p targeted and suppressed the NASP gene, and reduced viability, migration, invasion and EMT in HNSCC cells [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

The circular RNA hsa_circ_000780 as a potential molecular diagnostic target for gastric cancer

Song

Zhong

et al. 2021

BMC Med Genomics

View full text Add to dashboard Cite

Background The present study aimed to identify a specific circular RNA (circRNA) for early diagnosis of gastric cancer (GC). Methods Totally 82 patients with GC, 30 with chronic nonatrophic gastritis and 30 with chronic atrophic gastritis were included in this study. Four of the 82 GC patients were selected for screening. Total RNA from malignant and adjacent tissue samples was extracted, and circRNAs in four patients were screened. According to the screening results, the eight most upregulated and downregulated circRNAs with a statistically significant association with GC were identified by real-time fluorescent quantitative polymerase chain reaction (PCR). Then, the most regulated circRNA was selected for further sensitivity and specificity assessments. CircRNA expression was examined by quantitative reverse transcriptase PCR in 78 GC (21 and 57 early and advanced GC, respectively) and adjacent tissue samples, as well as in gastric fluid samples from 30 patients with chronic nonatrophic gastritis, 30 with chronic atrophic gastritis, and 78 GC. Results A total of 445 circRNAs, including 69 upregulated and 376 downregulated circRNAs, showed significantly altered expression in GC tissue samples. Hsa_circ_000780 was significantly downregulated in 80.77% of GC tissue samples, with levels in GC tissue samples correlating with tumor size, tumor stage, T stage, venous invasion, carcinoembryonic antigen amounts, and carbohydrate antigen 19–9 levels. Strikingly, this circRNA was found in the gastric fluid of patients with early and advanced GC. Conclusions The present study uncovered a new circRNA expression profile in human GC, with hsa_circ_000780 significantly downregulated in GC tissue and gastric fluid specimens. These findings indicate that hsa_circ_000780 should be considered a novel biomarker for early GC screening.

show abstract

MiR-381-3p/RAB2A axis activates cell proliferation and inhibits cell apoptosis in bladder cancer

Cited by 9 publications

References 31 publications

A serum miRNAs signature for early diagnosis of bladder cancer

A serum miRNAs signature for early diagnosis of bladder cancer

Identification and validation of RAB2A as a new prognostic biomarker for breast cancer

The circular RNA hsa_circ_000780 as a potential molecular diagnostic target for gastric cancer

Contact Info

Product

Resources

About